<![CDATA[Refluks laringofaring (RLF) adalah refluks cairan lambung melalui esofagus ke daerah laringofaring. Prevalensi RLF 15–20%, dan menjadi salah satu penyebab rinosinusitis kronik. Insidensi RLF pada penderita rinosinusitis kronik sebesar 37–72%. Prevalensi rinosinusitis kronik 16,3% pada dewasa dan berefek terhadap kualitas hidup. Omeprazol dan lansoprazol adalah proton pump inhibitor (PPI), digunakan sebagai terapi RLF, juga digunakan pada rinosinusitis kronik akibat RLF. Dilakukan penelitian periode Juni–Desember 2009. Penelitian ini merupakan randomized clinical trial dengan pengamatan open trial. Keikutsertaan 20 subjek penelitian dengan consecutive sampling, dibagi menjadi dua kelompok yang berbeda (dengan cara randomisasi sederhana) dalam pemberian PPI (omeprazol dan lansoprazol). Dilakukan pemeriksaan fisis THT, pengisian kuesioner sino-nasal outcome test 20, reflux symptom index, dan reflux finding score dengan menggunakan rinolaringoskopi serat lentur. Evaluasi setelah pemberian terapi 2 minggu dan 2 bulan. Data dianalisis dengan menggunakan uji Wilcoxon dan uji Mann-Whitney. Tidak terdapat perbedaan efektivitas antara omeprazol dan lansoprazol terhadap perbaikan derajat berat refluks laringofaring (p>0,05), namun perbaikan kualitas hidup pada kelompok perlakuan lansoprazol lebih baik bila dibandingkan dengan kelompok perlakuan omeprazol (p<0,05). Simpulan, lansoprazol lebih efektif dibandingkan dengan omeprazol dalam memperbaiki kualitas hidup pada penderita rinosinusitis kronik akibat RLF. [MKB. 2012;44(3):138–46].Kata kunci: Kualitas hidup, lansoprazol, omeprazol, refluks laringofaring, rinosinusitis kronik    Effectiveness Comparison between Omeprazole and Lansoprazole on the Improvement of Quality of Life in Patients with Chronic Rhinosinusitis Caused by Laryngopharyngeal RefluxLaryngopharyngeal reflux (LPR) is the reflux of gastric acid through the esophagus that reaches laringopharyngeal area. The prevalence of LPR in the range 15–20%, and caused chronic rhinosinusitis (CRS). The incidence of LPR in patients with CRS has ranged between 37–72%. The prevalence of CRS 16,3% in adults and affecting quality of life. Omeprazole and lansoprazole are  proton pump inhibitors (PPIs) for LPR’s therapy and also a therapy for CRS with LPR as the etiology. This research method was randomized clinical trial with open trial observation,  conducted in June to December 2009. Twenty subjects with consecutive sampling method, divided into two groups (with simple randomization), the first group received omeprazole and the other lansoprazole. The subjects conducted complete physical otolaryngology examination, sino-nasal outcome test 20, reflux symptom index and reflux finding score with fiber optic rhinolaryngoscopy. These data was obtained before therapy, after 2 weeks and  two months therapy,  analyzed with Wilcoxon’s  and Mann-Whitney’s test. There was no effectivity difference between omperazole and lansoprazole in reducing the level of severity of LPR (p>0.05), but quality of life improvement was better in lansoprazole than omeprazole group (p<0.05). In conclusion, lansoprazole is more effective than omeprazole in improvement of quality of life in patients with chronic rhinosinusitis caused by LPR. [MKB. 2012;44(3):138–46].Key words: Chronic rhinosinusitis, lansoprazole, laryngopharyngeal reflux, omeprazole, quality of life DOI: http://dx.doi.org/10.15395/mkb.v44n3.135]]>
